Park JE - Search Results

1

PSMB9 codon 60 polymorphisms have no impact on the activity of the immunoproteasome catalytic subunit B1i expressed in multiple types of solid cancer.

Park JE, Ao L, Miller Z, Kim K, Wu Y, Jang ER, Lee EY, Kim KB, Lee W. Park JE, et al. PLoS One. 2013 Sep 9;8(9):e73732. doi: 10.1371/journal.pone.0073732. eCollection 2013. PLoS One. 2013. PMID: 24040045 Free PMC article.

2

A FRET-based approach for identification of proteasome catalytic subunit composition.

Park JE, Wu Y, Carmony KC, Miller Z, Sharma LK, Lee DM, Kim DY, Lee W, Kim KB. Park JE, et al. Mol Biosyst. 2014 Feb;10(2):196-200. doi: 10.1039/c3mb70471h. Mol Biosyst. 2014. PMID: 24301521 Free PMC article.

3

Elucidating the catalytic subunit composition of distinct proteasome subtypes: a crosslinking approach employing bifunctional activity-based probes.

Cornish Carmony K, Sharma LK, Lee DM, Park JE, Lee W, Kim KB. Cornish Carmony K, et al. Among authors: park je. Chembiochem. 2015 Jan 19;16(2):284-92. doi: 10.1002/cbic.201402491. Epub 2014 Dec 4. Chembiochem. 2015. PMID: 25477005 Free PMC article.

4

H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth.

Lee MJ, Miller Z, Park JE, Bhattarai D, Lee W, Kim KB. Lee MJ, et al. Among authors: park je. Sci Rep. 2019 Mar 11;9(1):4089. doi: 10.1038/s41598-019-40635-1. Sci Rep. 2019. PMID: 30858500 Free PMC article.

5

Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice.

Park JE, Chun SE, Reichel D, Min JS, Lee SC, Han S, Ryoo G, Oh Y, Park SH, Ryu HM, Kim KB, Lee HY, Bae SK, Bae Y, Lee W. Park JE, et al. Among authors: park sh. PLoS One. 2017 Mar 8;12(3):e0173247. doi: 10.1371/journal.pone.0173247. eCollection 2017. PLoS One. 2017. PMID: 28273121 Free PMC article.

6

Next-generation proteasome inhibitors for cancer therapy.

Park JE, Miller Z, Jun Y, Lee W, Kim KB. Park JE, et al. Transl Res. 2018 Aug;198:1-16. doi: 10.1016/j.trsl.2018.03.002. Epub 2018 Mar 26. Transl Res. 2018. PMID: 29654740 Free PMC article. Review.

7

Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib.

Lee MJ, Bhattarai D, Yoo J, Miller Z, Park JE, Lee S, Lee W, Driscoll JJ, Kim KB. Lee MJ, et al. Among authors: park je. J Med Chem. 2019 May 9;62(9):4444-4455. doi: 10.1021/acs.jmedchem.8b01943. Epub 2019 Apr 19. J Med Chem. 2019. PMID: 30964987 Free PMC article.

8

Alternative Splicing: Expanding Diversity in Major ABC and SLC Drug Transporters.

Park JE, Ryoo G, Lee W. Park JE, et al. AAPS J. 2017 Nov;19(6):1643-1655. doi: 10.1208/s12248-017-0150-0. Epub 2017 Oct 2. AAPS J. 2017. PMID: 28971357 Review.

9

The N-terminal region of organic anion transporting polypeptide 1B3 (OATP1B3) plays an essential role in regulating its plasma membrane trafficking.

Chun SE, Thakkar N, Oh Y, Park JE, Han S, Ryoo G, Hahn H, Maeng SH, Lim YR, Han BW, Lee W. Chun SE, et al. Among authors: park je. Biochem Pharmacol. 2017 May 1;131:98-105. doi: 10.1016/j.bcp.2017.02.013. Epub 2017 Feb 23. Biochem Pharmacol. 2017. PMID: 28216016

10

Enhancing Docetaxel Delivery to Multidrug-Resistant Cancer Cells with Albumin-Coated Nanocrystals.

Gad SF, Park J, Park JE, Fetih GN, Tous SS, Lee W, Yeo Y. Gad SF, et al. Among authors: park je, park j. Mol Pharm. 2018 Jan 29:10.1021/acs.molpharmaceut.7b00783. doi: 10.1021/acs.molpharmaceut.7b00783. Online ahead of print. Mol Pharm. 2018. PMID: 29341617 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,216 results

Search Page

Filters